trial
as of 2026-07-01A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
NCTId NCT00637494
at a glance
Phase 3 · Terminated
Enrollment 292 (actual)
Sponsored by Corcept Therapeutics
Primary completion 2014-06
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Terminated
Enrollment
292 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2008-03
Primary completion
2014-06
Eligibility
ALL · 22 Years
Interventions & indications
Sponsors
Corcept TherapeuticsLead Sponsor
Investigators
1
Thaddeus Block, MDStudy Director
Sites
42 total
Little Rock, United StatesLittle Rock, United StatesAnaheim, United StatesDowney, United StatesEscondido, United StatesGarden Grove, United StatesOakland, United StatesOceanside, United StatesSan Bernardino, United StatesSan Diego, United StatesSan Diego, United StatesAventura, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
292
Phase
PHASE3
Primary Completion Date
2014-06
Status
TERMINATED
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication
indication
indication
investigator
person